Encompass Health Co. (EHC) To Go Ex-Dividend on July 1st

Encompass Health Co. (NYSE:EHC) announced a quarterly dividend on Thursday, May 2nd, Zacks reports. Investors of record on Monday, July 1st will be paid a dividend of 0.15 per share on Monday, July 15th. This represents a $0.60 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Monday, July 1st.

Encompass Health has decreased its dividend payment by an average of 18.8% annually over the last three years. Encompass Health has a dividend payout ratio of 13.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Encompass Health to earn $4.57 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 13.1%.

Encompass Health Stock Performance

Shares of EHC stock opened at $85.83 on Friday. The company has a market capitalization of $8.64 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 1.34 and a beta of 0.90. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.37 and a current ratio of 1.37. The company has a 50-day simple moving average of $84.77 and a 200 day simple moving average of $77.43. Encompass Health has a 52 week low of $57.55 and a 52 week high of $87.94.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Wednesday, April 24th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The business had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter in the previous year, the company earned $0.88 EPS. The business’s revenue was up 13.4% on a year-over-year basis. On average, sell-side analysts predict that Encompass Health will post 4.1 earnings per share for the current year.

Insider Activity

In related news, CEO Mark J. Tarr sold 44,976 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now directly owns 554,098 shares of the company’s stock, valued at $46,139,740.46. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Encompass Health news, insider Elissa Joy Charbonneau sold 10,000 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $85.02, for a total transaction of $850,200.00. Following the transaction, the insider now owns 18,594 shares in the company, valued at $1,580,861.88. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Mark J. Tarr sold 44,976 shares of the company’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $83.27, for a total transaction of $3,745,151.52. Following the transaction, the chief executive officer now owns 554,098 shares in the company, valued at approximately $46,139,740.46. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,519 shares of company stock valued at $5,816,091. 2.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on EHC shares. Mizuho boosted their target price on shares of Encompass Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Royal Bank of Canada boosted their target price on shares of Encompass Health from $83.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, May 22nd. Barclays boosted their target price on shares of Encompass Health from $101.00 to $108.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Stephens restated an “overweight” rating and issued a $94.00 target price on shares of Encompass Health in a research report on Wednesday, June 5th. Finally, Raymond James restated a “strong-buy” rating and issued a $95.00 target price (up from $85.00) on shares of Encompass Health in a research report on Friday, April 26th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $93.29.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.